PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-7.45%
Revenue decline while Medical - Pharmaceuticals median is 1.38%. Seth Klarman would investigate if market share loss is temporary.
-8.29%
Cost reduction while Medical - Pharmaceuticals median is 1.79%. Seth Klarman would investigate competitive advantage potential.
-3.98%
Gross profit decline while Medical - Pharmaceuticals median is 1.25%. Seth Klarman would investigate competitive position.
3.75%
Margin change of 3.75% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.38%
Other expenses change of 50.38% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
2.63%
Operating expenses growth near Medical - Pharmaceuticals median of 2.55%. Charlie Munger would verify industry norms.
-6.69%
Total costs reduction while Medical - Pharmaceuticals median is 4.82%. Seth Klarman would investigate advantages.
18.18%
Interest expense change of 18.18% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
45.36%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.64%. Jim Chanos would check for overinvestment.
-17.81%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.19%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-20.34%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-13.92%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
33.20%
Other expenses change of 33.20% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-17.88%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.27%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.25%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-18.30%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.72%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-18.29%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-18.29%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.